Type of non Hodgkin's lymphoma-Other-Marginal zone B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Other-Marginal zone B-cell lymphoma Posts on Medivizor

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Posted by on Jul 30, 2023 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of polatuzumab vedotin (PV; Polivy) combined with dose-adjusted EPOCH-R chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The data showed that PV combined with dose-adjusted EPOCH-R...

Read More

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

Posted by on Nov 21, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients.  Some background B-NHL is a type of...

Read More

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Posted by on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL).   This study concluded that this treatment can be effective in these patients.   Some background Radiotherapy (RT) is an important treatment in managing patients...

Read More

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...

Read More

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Posted by on Dec 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).   This study concluded that this combination was safe and effective in these...

Read More

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Posted by on Oct 4, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of 177Lu-lilotomab satetraxetan (177LLS; Betalutin) in patients with relapsed/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL). The main finding was that 177LLS was proven to be a valuable alternative treatment in such patients. Some background NHL is a type of lymphoma that spreads...

Read More

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Posted by on Sep 13, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the effectiveness and safety of lisocabtagene maraleucel (Liso-cel) in treating patients with relapsed or refractory (r/r) large B-cell lymphomas (LBCL). The authors found that liso-cel achieved fast and lasting remission with fewer toxicities in such patients. Some background Patients with r/r-LBCL experience...

Read More

Treating patients with B-cell non-Hodgkin lymphoma with immunoglobulin replacement therapy after rituximab treatment

Treating patients with B-cell non-Hodgkin lymphoma with immunoglobulin replacement therapy after rituximab treatment

Posted by on Sep 6, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the outcomes of immunoglobulin replacement (IgR) therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL) and immunodeficiency, who were previously treated with rituximab (Rituxan). The authors found that IgR was safe and effective to increase serum immunoglobulins in such patients. Some background B-NHL happens...

Read More

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Posted by on Jul 28, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at axicabtagene ciloleucel (Yescarta) to treat B-cell non-Hodgkin lymphoma which has returned after previous treatment outside of clinical trials. It found that most patients responded to this immune therapy and that some patients had a complete response. Some background B-cell non-Hodgkin lymphomas (NHL) are a group of...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2025 Medivizor